10,188 Shares in The Chemours Company $CC Acquired by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC purchased a new position in The Chemours Company (NYSE:CC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,188 shares of the specialty chemicals company’s stock, valued at approximately $117,000.

A number of other institutional investors also recently added to or reduced their stakes in CC. FNY Investment Advisers LLC purchased a new stake in shares of Chemours during the 1st quarter worth approximately $27,000. Farther Finance Advisors LLC lifted its position in shares of Chemours by 170.7% during the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock worth $30,000 after buying an additional 1,444 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock worth $30,000 after buying an additional 948 shares during the last quarter. SouthState Corp purchased a new stake in shares of Chemours during the 1st quarter worth approximately $34,000. Finally, Parallel Advisors LLC lifted its position in shares of Chemours by 132.6% during the 2nd quarter. Parallel Advisors LLC now owns 5,634 shares of the specialty chemicals company’s stock worth $65,000 after buying an additional 3,212 shares during the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Chemours Stock Performance

Shares of Chemours stock opened at $15.66 on Friday. The firm’s fifty day simple moving average is $14.79 and its 200-day simple moving average is $12.94. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -5.59 and a beta of 1.61. The Chemours Company has a 12 month low of $9.13 and a 12 month high of $22.38. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.12. The business had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 15th were paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Friday, August 15th. Chemours’s payout ratio is currently -12.50%.

Analyst Upgrades and Downgrades

CC has been the subject of several recent analyst reports. Truist Financial boosted their price objective on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Mizuho boosted their price objective on shares of Chemours from $16.00 to $19.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Royal Bank Of Canada boosted their price objective on shares of Chemours from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Thursday, July 3rd. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Insider Transactions at Chemours

In other news, CEO Denise Dignam acquired 4,068 shares of the company’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $12.06 per share, with a total value of $49,060.08. Following the purchase, the chief executive officer owned 191,546 shares of the company’s stock, valued at $2,310,044.76. This represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.47% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.